The push for autonomous vehicles (AVs) to be embraced as a public health imperative is gaining momentum, with two prominent doctors advocating for their widespread adoption. Jonathan Slotkin, a neurosurgeon and chief medical officer, and Eric Topol, a cardiologist and health tech commentator, have joined forces to urge policymakers to prioritize AV deployment. Their argument is compelling, emphasizing the technology's potential to save lives and reduce serious injuries on the road.
In an open letter, they highlight the significant reduction in serious-injury crashes and incidents involving pedestrians and cyclists, citing a 2025 study by Waymo, an AV industry leader. The study, which analyzed 56.7 million fully driverless miles on public roads, revealed an impressive 85% decrease in serious-injury-or-worse crashes compared to human drivers. This data is crucial, as it demonstrates the tangible benefits of AVs in enhancing road safety.
However, the doctors emphasize that AVs are not a panacea for all safety issues. Instead, they argue that the accumulating evidence of their safety merits immediate action. The letter calls for standardized federal data-reporting requirements, allowing for meaningful comparisons between different AV companies. This transparency is essential to build trust and ensure the technology's effectiveness.
The doctors also address the regulatory barriers imposed by some states, such as New York, Massachusetts, Washington, Minnesota, and Washington, D.C., which have blocked robotaxi deployment. They advocate for evidence-based frameworks that prioritize safety and encourage AV deployment where it is supported by data. This approach ensures that decisions are made based on facts rather than unfounded concerns.
Slotkin's personal connection to the issue is profound. As a neurosurgeon, he has witnessed the devastating consequences of car crashes, including injuries to children. His advocacy stems from a place of empathy and a desire to make a tangible impact on public health. Despite criticism that his previous essay in The New York Times was perceived as pro-Waymo, he asserts that his and Topol's advocacy is driven by a genuine commitment to improving road safety.
In conclusion, the doctors' call to action is a significant development in the AV industry's push for widespread adoption. Their emphasis on public health and evidence-based decision-making is a refreshing perspective in a field often mired in debate and uncertainty. As the AV industry continues to evolve, the voices of medical professionals like Slotkin and Topol will play a crucial role in shaping public perception and policy, ultimately contributing to a safer and more efficient transportation future.
